Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc (ABOS) Covered Calls
Read more
Running ABOS covered calls helps you generate income from Acumen Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ABOS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ABOS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABOS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ABOS covered call is worth writing.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
No illustrative rows to display.
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank96.43% High
- Market cap (M$)15
- 52 weeks high-94.17%
- 52 weeks low10.53%
- Analyst recommendationHold
3.20 - Target price$1.00
376.19% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-10-26
- P/E—
- Future P/E—
- EPS (ttm)-1.55
- EPS growth next 5 years50.45%
As of Nov 13, 2026